Top

Cancer Cell International

Published in:

01-12-2020 | Endometrial Cancer | Primary research

BTG1 inhibits malignancy as a novel prognosis signature in endometrial carcinoma

Authors: Yibing Li, Jianing Huo, Junjian He, Yunzheng Zhang, Xiaoxin Ma

Published in: Cancer Cell International | Issue 1/2020

Abstract

Background

Endometrial carcinoma (EC) is one of the three major malignant tumors of the female reproductive system. In recent years, the incidence and mortality rate of EC have increased. B-cell translocation gene 1 (BTG1) is an anti-proliferation gene that regulates the occurrence and development of a variety of tumors, but there is no research regarding this gene in EC.

Methods

Based on The Cancer Genome Atlas (TCGA) database, we used a variety of bioinformatics tools and databases to explore the expression and prognosis of BTG1. We verified expression and prognosis of BTG1 in EC using qRT-PCR and analyzed the relevant clinicopathological parameters. We functionally enriched BTG1 and related genes in EC patients through the bioinformatics website and analyzed miRNA targets of BTG1 and interacting protein networks. Cell proliferation, wound healing, transwell invasion, and cell apoptosis assays were used to detect the effects of BTG1 on the malignant biological behavior of endometrial carcinoma cells (ECCs). The effect of BTG1 on the epithelial-to-mesenchymal transition (EMT) process was detected using western blot.

Results

We analyzed the expression and prognosis of BTG1 based on TCGA and found that low expression of BTG1 was associated with poor EC prognosis. The qRT-PCR suggested that BTG1 had low expression in EC. BTG1 expression was significantly correlated with overall survival (OS) shortening. Clinicopathological analysis suggested that expression of BTG1 was related to invasion depth and the International Federation of Gynecology and Obstetrics (FIGO) stage. EC pathological tissue type, fertility history, lymphatic metastasis, menopause, estrogen receptor (ER), progesterone receptor (PR), and age of diagnosis were not related. Functional enrichment analysis showed that BTG1 plays an important role in regulating embryonic development, tumorigenesis, apoptosis, and cell cycle. Biological behavior experiments suggest that BTG1 inhibits proliferation, migration, and invasion of ECCs, and promotes apoptosis of ECCs. Western blot indicated that BTG1 inhibited the EMT process of ECCs.

Conclusions

BTG1, as a tumor suppressor gene, plays an important role in the occurrence and development of EC. We believe that BTG1 can be used as a potential prognostic biomarker for EC.

Available only for authorised users

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.CrossRefPubMed

Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2019: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2019;69(3):184–210. https://doi.org/10.3322/caac.21557.CrossRefPubMed

Koh WJ, Abu-Rustum NR, Bean S, et al. Uterine neoplasms, version 1.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16(2):170–99. https://doi.org/10.6004/jnccn.2018.0006.CrossRefPubMed

Coll-de la Rubia E, Martinez-Garcia E, Dittmar G, Gil-Moreno A, Cabrera S, Colas E. Prognostic biomarkers in endometrial cancer: a systematic review and meta-analysis. J Clin Med. 2020;9(6):E1900. https://doi.org/10.3390/jcm9061900.CrossRefPubMed

Berthet C, Guéhenneux F, Revol V, et al. Interaction of PRMT1 with BTG/TOB proteins in cell signalling: molecular analysis and functional aspects. Genes Cells. 2002;7(1):29–39. https://doi.org/10.1046/j.1356-9597.2001.00497.x.CrossRefPubMed

Winkler GS. The mammalian anti-proliferative BTG/Tob protein family. J Cell Physiol. 2010;222(1):66–72. https://doi.org/10.1002/jcp.21919.CrossRefPubMed

Micheli L, Ceccarelli M, Farioli-Vecchioli S, Tirone F. Control of the normal and pathological development of neural stem and progenitor cells by the PC3/Tis21/Btg2 and Btg1 genes. J Cell Physiol. 2015;230(12):2881–90. https://doi.org/10.1002/jcp.25038.CrossRefPubMed

Li W, Zou ST, Zhu R, Wan JM, Xu Y, Wu HR. B–cell translocation 1 gene inhibits cellular metastasis–associated behavior in breast cancer. Mol Med Rep. 2014;9(6):2374–80. https://doi.org/10.3892/mmr.2014.2118.CrossRefPubMed

Yuniati L, Scheijen B, van der Meer LT, van Leeuwen FN. Tumor suppressors BTG1 and BTG2: beyond growth control. J Cell Physiol. 2019;234(5):5379–89. https://doi.org/10.1002/jcp.27407.CrossRefPubMed

10.

Zheng HC, Li J, Shen DF, et al. BTG1 expression correlates with pathogenesis, aggressive behaviors and prognosis of gastric cancer: a potential target for gene therapy. Oncotarget. 2015;6(23):19685–705. https://doi.org/10.18632/oncotarget.4081.CrossRefPubMedPubMedCentral

11.

Sun G, Liu Q, Cheng Y, Hu W. B cell translocation gene 1 reduces the biological outcome of kidney cancer through induction of cell proliferation, cell cycle arrest, cell apoptosis and cell metastasis. Int J Mol Med. 2015;35(3):777–83. https://doi.org/10.3892/ijmm.2014.2058.CrossRefPubMed

12.

Sun GG, Lu YF, Cheng YJ, et al. Expression of BTG1 in hepatocellular carcinoma and its correlation with cell cycles, cell apoptosis, and cell metastasis. Tumour Biol. 2014;35(12):11771–9. https://doi.org/10.1007/s13277-014-2298-x.CrossRefPubMed

13.

Lu YF, Sun GG, Liu Q, Yang CR, Cheng YJ. BTG1 expression in thyroid carcinoma: diagnostic indicator and prognostic marker. Int J Oncol. 2014;45(4):1574–82. https://doi.org/10.3892/ijo.2014.2543.CrossRefPubMed

14.

Sun GG, Wang YD, Cheng YJ, Hu WN. The expression of BTG1 is downregulated in nasopharyngeal carcinoma and possibly associated with tumour metastasis. Mol Biol Rep. 2014;41(9):5979–88. https://doi.org/10.1007/s11033-014-3475-0.CrossRefPubMed

15.

Zhao Y, Gou WF, Chen S, Takano Y, Xiu YL, Zheng HC. BTG1 expression correlates with the pathogenesis and progression of ovarian carcinomas. Int J Mol Sci. 2013;14(10):19670–80. https://doi.org/10.3390/ijms141019670.CrossRefPubMedPubMedCentral

16.

Zhu R, Zou ST, Wan JM, Li W, Li XL, Zhu W. BTG1 inhibits breast cancer cell growth through induction of cell cycle arrest and apoptosis. Oncol Rep. 2013;30(5):2137–44. https://doi.org/10.3892/or.2013.2697.CrossRefPubMed

17.

Sun GG, Lu YF, Cheng YJ, Hu WN. The expression of BTG1 is downregulated in NSCLC and possibly associated with tumor metastasis. Tumour Biol. 2014;35(4):2949–57. https://doi.org/10.1007/s13277-013-1379-6.CrossRefPubMed

18.

Wang Y, Sun W, Yang J, et al. PUM2 promotes glioblastoma cell proliferation and migration via repressing BTG1 expression. Cell Struct Funct. 2019;44(1):29–39. https://doi.org/10.1247/csf.18030.CrossRefPubMed

19.

Zhu J, Han S. Lidocaine inhibits cervical cancer cell proliferation and induces cell apoptosis by modulating the lncRNA-MEG3/miR-421/BTG1 pathway. Am J Transl Res. 2019;11(9):5404–16.PubMedPubMedCentral

20.

Rhodes DR, Kalyana-Sundaram S, Mahavisno V, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007;9(2):166–80.CrossRefPubMedPubMedCentral

21.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–102. https://doi.org/10.1093/nar/gkx247.CrossRefPubMedPubMedCentral

22.

Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649–58. https://doi.org/10.1016/j.neo.2017.05.002.CrossRefPubMedPubMedCentral

23.

Goel MK, Khanna P, Kishore J. Understanding survival analysis: Kaplan–Meier estimate. Int J Ayurveda Res. 2010;1(4):274–8. https://doi.org/10.4103/0974-7788.76794.CrossRefPubMedPubMedCentral

24.

Vasaikar SV, Straub P, Wang J, Zhang B. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2018;46(D1):D956–63. https://doi.org/10.1093/nar/gkx1090.CrossRefPubMed

25.

Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523. https://doi.org/10.1038/s41467-019-09234-6.CrossRefPubMedPubMedCentral

26.

Warde-Farley D, Donaldson SL, Comes O, et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 2010;38(4):W214–20. https://doi.org/10.1093/nar/gkq537.CrossRefPubMedPubMedCentral

27.

Wong N, Wang X. miRDB: an online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 2015;43(Database issue):D146–52. https://doi.org/10.1093/nar/gku1104.CrossRefPubMed

28.

Pan X, Li D, Huo J, Kong F, Yang H, Ma X. LINC01016 promotes the malignant phenotype of endometrial cancer cells by regulating the miR-302a-3p/miR-3130-3p/NFYA/SATB1 axis. Cell Death Dis. 2018;9(3):303. https://doi.org/10.1038/s41419-018-0291-9.CrossRefPubMedPubMedCentral

29.

Li Y, Huo J, Pan X, Wang C, Ma X. MicroRNA 302b-3p/302c-3p/302d-3p inhibits epithelial-mesenchymal transition and promotes apoptosis in human endometrial carcinoma cells. Onco Targets Ther. 2018;11:1275–84. https://doi.org/10.2147/ott.s154517.CrossRefPubMedPubMedCentral

30.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. https://doi.org/10.3322/caac.21551.CrossRefPubMed

31.

Braun MM, Overbeek-Wager EA, Grumbo RJ. Diagnosis and management of endometrial cancer. Am Fam Physician. 2016;93(6):468–74.PubMed

32.

Zhang J, Dong W. Expression of B cell translocation gene 1 protein in colon carcinoma and its clinical significance. Recent Pat Anticancer Drug Discov. 2020;15(1):78–85. https://doi.org/10.2174/1574892815666200109113114.CrossRefPubMed

33.

Qian Y, Lu X, Li Q, Zhao S, Fang D. The treatment effects and the underlying mechanism of B cell translocation gene 1 on the oncogenesis of brain glioma. J Cell Biochem. 2019;120(8):13310–20. https://doi.org/10.1002/jcb.28605.CrossRefPubMed

34.

Kanda M, Sugimoto H, Nomoto S, et al. B–cell translocation gene 1 serves as a novel prognostic indicator of hepatocellular carcinoma. Int J Oncol. 2015;46(2):641–8. https://doi.org/10.3892/ijo.2014.2762.CrossRefPubMed

35.

Kanda M, Oya H, Nomoto S, et al. Diversity of clinical implication of B-cell translocation gene 1 expression by histopathologic and anatomic subtypes of gastric cancer. Dig Dis Sci. 2015;60(5):1256–64. https://doi.org/10.1007/s10620-014-3477-8.CrossRefPubMed

36.

Zhu R, Li W, Xu Y, Wan J, Zhang Z. Upregulation of BTG1 enhances the radiation sensitivity of human breast cancer in vitro and in vivo. Oncol Rep. 2015;34(6):3017–24. https://doi.org/10.3892/or.2015.4311.CrossRefPubMed

37.

Cesareni G, Panni S, Nardelli G, Castagnoli L. Can we infer peptide recognition specificity mediated by SH3 domains? FEBS Lett. 2002;513:38–44. https://doi.org/10.1016/S0014-5793(01)03307-5.CrossRefPubMed

38.

Li H, Zhang M, Wei Y, et al. SH3BGRL confers innate drug resistance in breast cancer by stabilizing HER2 activation on cell membrane. J Exp Clin Cancer Res. 2020;39(1):81. https://doi.org/10.1186/s13046-020-01577-z.CrossRefPubMedPubMedCentral

39.

Chang YS, Huang HD, Yeh KT, Chang JG. Identification of novel mutations in endometrial cancer patients by whole-exome sequencing. Int J Oncol. 2017;50(5):1778–84. https://doi.org/10.3892/ijo.2017.3919.CrossRefPubMed

40.

Zhu X, Li S. TET2 inhibits tumorigenesis of breast cancer cells by regulating caspase-4. Sci Rep. 2018;8:16167.CrossRefPubMedPubMedCentral

41.

Jia J, Shi Y, Chen L, et al. Decrease in lymphoid specific helicase and 5-hydroxymethylcytosine is associated with metastasis and genome instability. Theranostics. 2017;7(16):3920–32. https://doi.org/10.7150/thno.21389.CrossRefPubMedPubMedCentral

42.

Zhang X, Yang J, Shi D, Cao Z. TET2 suppresses nasopharyngeal carcinoma progression by inhibiting glycolysis metabolism. Cancer Cell Int. 2020;20:363. https://doi.org/10.1186/s12935-020-01456-9.CrossRefPubMedPubMedCentral

43.

Sha S, Gu Y, Xu B, et al. Decreased expression of HOXB9 is related to poor overall survival in patients with gastric carcinoma. Dig Liver Dis. 2013;45(5):422–9. https://doi.org/10.1016/j.dld.2012.12.004.CrossRefPubMed

44.

Hayashida T, Takahashi F, Chiba N, et al. HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis. Proc Natl Acad Sci USA. 2010;107(3):1100–5. https://doi.org/10.1073/pnas.0912710107.CrossRefPubMed

45.

Chiba N, Comaills V, Shiotani B, et al. Homeobox B9 induces epithelial-to-mesenchymal transition-associated radioresistance by accelerating DNA damage responses. Proc Natl Acad Sci USA. 2012;109(8):2760–5. https://doi.org/10.1073/pnas.1018867108.CrossRefPubMed

46.

Shrestha B, Ansari KI, Bhan A, Kasiri S, Hussain I, Mandal SS. Homeodomain-containing protein HOXB9 regulates expression of growth and angiogenic factors, facilitates tumor growth in vitro and is overexpressed in breast cancer tissue. FEBS J. 2012;279(19):3715–26. https://doi.org/10.1111/j.1742-4658.2012.08733.x.CrossRefPubMedPubMedCentral

47.

Wan J, Liu H, Feng Q, Liu J, Ming L. HOXB9 promotes endometrial cancer progression by targeting E2F3. Cell Death Dis. 2018;9(5):509. https://doi.org/10.1038/s41419-018-0556-3.CrossRefPubMedPubMedCentral

48.

Huang Y, Zheng J, Tan T, et al. BTG1 low expression in pancreatic ductal adenocarcinoma is associated with a poorer prognosis. Int J Biol Markers. 2018;33(2):189–94. https://doi.org/10.5301/ijbm.5000310.CrossRefPubMed

49.

Su C, Huang DP, Liu JW, Liu WY, Cao YO. miR-27a-3p regulates proliferation and apoptosis of colon cancer cells by potentially targeting BTG1. Oncol Lett. 2019;18(3):2825–34. https://doi.org/10.3892/ol.2019.10629.CrossRefPubMedPubMedCentral

50.

Xu Y, Zhang G, Zou C, et al. Long noncoding RNA DGCR5 suppresses gastric cancer progression by acting as a competing endogenous RNA of PTEN and BTG1. J Cell Physiol. 2019;234(7):11999–2010. https://doi.org/10.1002/jcp.27861.CrossRefPubMed

51.

Zhang Y, Weinberg RA. Epithelial-to-mesenchymal transition in cancer: complexity and opportunities. Front Med. 2018;12(4):361–73. https://doi.org/10.1007/s11684-018-0656-6.CrossRefPubMedPubMedCentral

Title: BTG1 inhibits malignancy as a novel prognosis signature in endometrial carcinoma
Authors: Yibing Li
Jianing Huo
Junjian He
Yunzheng Zhang
Xiaoxin Ma
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Endometrial Cancer
Endometrial Cancer
Published in: Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-020-01591-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

ZKSCAN3 drives tumor metastasis via integrin β4/FAK/AKT mediated epithelial–mesenchymal transition in hepatocellular carcinoma

LncRNA LINC00261 overexpression suppresses the growth and metastasis of lung cancer via regulating miR-1269a/FOXO1 axis

MiR-4310 induced by SP1 targets PTEN to promote glioma progression

MCM3AP-AS1/miR-876-5p/WNT5A axis regulates the proliferation of prostate cancer cells

Zoledronic acid inhibits TSC2-null cell tumor growth via RhoA/YAP signaling pathway in mouse models of lymphangioleiomyomatosis

Evaluation of the potential role of long non-coding RNA LINC00961 in luminal breast cancer: a case–control and systems biology study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer